Pharmaceuticals, Biotechnology and Life Sciences
Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated…
Daiichi Sankyo’s test of HER3 antibody drug conjugate U3-1402 data suggest that targeting HER3 with may be an effective treatment strategy irrespective of mechanism of resistance identified in the setting of EGFR TKI resistance, where new precision treatments are needed, said Helena Yu, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, and a trial investigator.
Merck, a leading science and technology company, today announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first…
BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient…
COLOGNE, Germany–(BUSINESS WIRE)–On September 9th, Cannamedical® Pharma GmbH, a leading cannabis distributor and one of the best-known medicinal cannabis brands…
Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp®…
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on…
— The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold — SEATTLE–(BUSINESS WIRE)–Omeros Corporation…
SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that…